Londei Marco
Institute of Child Health, University College London, London, UK.
Arthritis Res Ther. 2005;7(3):118-20. doi: 10.1186/ar1745. Epub 2005 Apr 7.
CD4+CD25+ T regulatory cells are avidly studied because they modulate immune responses. Their possible role in autoimmunity and more specifically in rheumatoid arthritis (RA) has been highlighted by a string of reports, one of which is in the last issue of Arthritis Research & Therapy. There are, however, key questions that have not yet been addressed before their use can be considered as a real therapeutic option. The first is the actual, in a clinical setting, efficacy of Treg to treat active chronic autoimmune diseases such as RA. The second is how we can practically deliver their therapeutic activity in patients. Once these points have been addressed we will have a new and potentially very effective 'magic bullet' for the treatment of chronic autoimmune diseases.
CD4+CD25+调节性T细胞因其能调节免疫反应而受到广泛研究。一系列报告突出了它们在自身免疫性疾病，尤其是类风湿性关节炎（RA）中可能发挥的作用，其中一篇发表在《关节炎研究与治疗》的上一期。然而，在将其作为一种真正的治疗选择加以考虑之前，仍有一些关键问题尚未得到解决。第一个问题是，在临床环境中，调节性T细胞治疗诸如类风湿性关节炎这类活动性慢性自身免疫性疾病的实际疗效如何。第二个问题是，我们如何在患者身上切实发挥它们的治疗作用。一旦这些问题得到解决，我们将拥有一种治疗慢性自身免疫性疾病的全新且可能非常有效的“神奇子弹”。
